DNDI asaq
Updates
October 2008asaq 2008
  • ASAQ has been granted 'prequalified' status by the WHO Prequalification Program
  • ASAQ: approved in 21 African countries; over 3 million treatments distributed into the field
read more
videos
ASAQ in a few words
- A drug combination that meets the latest WHO guidelines for malaria treatment in Africa

- An innovative fixed-dose formulation
A simple dosing regimen:
  • 1 tablet per day for 3 days for infants, children and adolescents
  • 2 tablets once a day for 3 days for adults
    Presentations specifically adapted to children
  • State-of-the-art galenical formulation
  • Optimized dose ratio to avoid over- and under-dosage

In the child’s lower hand, the single ASAQ tablet per day is shown in comparison with the upper hand containing 4 tablets needed per day with current treatments.
- A combination of well-known drugs with well-documented track records
of efficacy and safety

- A commitment to make it available to all patients, right from the start
  • <US$1 for adults and <US$0.50 for children in public markets
  • Not patented
- Highest standards of quality enforced through the entire manufacturing process

- The concrete result of an innovative partnership between DNDi and
sanofi-aventis

Version française English version
asaq asaq
contents
 
Updates
Press release
Videos
ASAQ in a few words
ASAQ product profile
ASAQ... Adapted
ASAQ...Simple
ASAQ... Accessible
ASAQ... Quality
Clinical Data
An innovative partnership
ASAQ: Contribution of DNDi
and FACT Partners
ASAQ: Contribution of sanofi-aventis
DNDi: addressing the therapeutic needs of the most neglected
sanofi-aventis
Background on malaria
ASAQ in the media
Governments welcome ASAQ!ItalyGermanyEuropean UnionUnited KingdomNetherlands
MSF welcomes ASAQ
Product launch
dates to be aware of

Paris - 1 March
11 am - 1pm: Press briefing
Centre d'Accueil de la Presse Étrangère - Maison de Radio France
Paris - 1 March
6 pm - 7:30 pm: Expert Roundtable "Transforming Hope into Equitable Access for Malaria Patients in Africa" la Maison Internationale Cite Universitaire
Washington DC - 9 March
8 am -9:30 am
plos
Read the PLoS guest blog of Jean-René Kiechel & Bernard Pecoul:
"Innovative Partnership Brings New ACT Free of Patent"
Original FACT Partners
(who signed onto the original EU INCO-DEV grant in 2002):
Instituto de Tecnologia em Farmacos of Farmanguinhos Centre National de Recherche et de Formation sur le Paludisme (CNRFP) Mahidol University Médecins Sans Frontières UNICEF-UNDP-World Bank-WHO's Special Programme for Research and Training in Tropical Diseases (TDR) Université Victor Segalen Bordeaux II (TROPIVAL) University of Oxford University Sains Malaysia Since the main FACT partners formed in 2002, many additional partners are contributing to this project.read more
Links of related interest: London School of Hygiene & Tropical Medicine Malaria Consortium Medicines for Malaria Venture (MMV) MSF Access President's Malaria Initiative Roll Back Malaria UNITAID WHO Global Malaria Programme (GMP)
asaq